DiaMedica Therapeutics Inc.
No SEC Form 4 filings for $DMAC in the last 30 days.
See all $DMAC insider activity →DiaMedica Therapeutics Inc. (DMAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1001907.htm EXHIBIT 99.1 ex_1001907.htm Exhibit 99.1 DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights ● Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader
This article provides the EBITDA per share information for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). The content appears to be a financial data snippet from TradingView, focusing on key financial metrics for the specified biotechnology company.
DiaMedica Therapeutics Inc. announced its participation in three upcoming investor conferences in March 2026. Company management, including CEO Rick Pauls and Chief Medical Officer Julie Krop, will engage in fireside chats and presentations at events hosted by TD Cowen, Barclays, and Leerink Partners to discuss their clinical-stage biopharmaceutical developments. The company focuses on novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke with their lead candidate DM199.
Over the past 7 days, alphai's AI scored 1 news story mentioning DMAC (DiaMedica Therapeutics Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DMAC coverage spans financial news and earnings.
Clinical readouts and regulatory progress increase the probability of advancing DM199 into further cohorts and Phase 3 dose selection, while cash runway reduces near-term financing risk.
The reported EBITDA per share for DiaMedica Therapeutics Inc. (NASDAQ: DMAC) indicates a stable financial position, with no immediate signs of distress or extraordinary profitability. Given the neutral market sentiment, the stock's short-term movement is likely to remain sideways unless new catalysts emerge.
DiaMedica Therapeutics (DMAC) is participating in multiple investor conferences in March 2026, highlighting ongoing clinical developments and management engagement. The company's focus on novel treatments for preeclampsia, fetal growth restriction, and stroke may attract investor interest.
DiaMedica Therapeutics (DMAC) shows signs of positive momentum driven by favorable sentiment and recent developments. The stock exhibits bullish indicators, suggesting potential for short-term gains.
The recent golden cross in DiaMedica Therapeutics (DMAC) suggests a bullish technical outlook, potentially signaling upward price movement.
alphai scores every news story that mentions DMAC with an AI model for sentiment and relevance, and aggregates insider trades from DiaMedica Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DiaMedica Therapeutics Inc. (DMAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1001907.htm EXHIBIT 99.1 ex_1001907.htm Exhibit 99.1 DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights ● Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader
6 min readThis article provides the EBITDA per share information for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). The content appears to be a financial data snippet from TradingView, focusing on key financial metrics for the specified biotechnology company.
2 min readDiaMedica Therapeutics Inc. announced its participation in three upcoming investor conferences in March 2026. Company management, including CEO Rick Pauls and Chief Medical Officer Julie Krop, will engage in fireside chats and presentations at events hosted by TD Cowen, Barclays, and Leerink Partners to discuss their clinical-stage biopharmaceutical developments. The company focuses on novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke with their lead candidate DM199.
2 min readDoes DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 min readWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
2 min readThe mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 min readDoes DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 min readThe mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2 min readDiaMedica Therapeutics ( NASDAQ:DMAC ) , a clinical-stage biopharmaceutical company focused on developing treatments for serious unmet medical needs, released its second quarter results on August 12, 2025. The headline news was a net loss per share of $ ( 0.18 ) ( GAAP ) for the quarter, which ...
2 min read
